Our analysts (or “bakers”) compete in a Great British Bake Off–style episode, discussing why Dr. Google will give way to Dr. ChatGPT in 2026 and how Americans will increasingly use AI for mental health therapy and support this year. Join Senior Director of Podcasts and host Marcus Johnson, along with Senior Analysts Rajiv Leventhal and Beth Snyder Bulik. Listen everywhere, and watch on YouTube and Spotify.
The first year of Trump’s second term has brought disruption and uncertainty, reshaping retail, media advertising, tech, health, and financial services.
More than a third of patients will switch doctors who don’t modernize the experience.
The biggest women’s health opportunity may actually be in common diseases that affect women differently and go ignored.
Rigorous data gives acetaminophen brands footing to reassure pregnant consumers.
The riff on Apple’s Mac versus PC campaign lightens the pharma tone while also leaning more into disclosures.
Novo and Lilly prohibit telehealth partners from offering compounded GLP-1s, eroding compounders’ ability to distribute.
AI’s growing clout in healthcare and pharma and candid confessions from drugmaker CEOs dominated the narrative at JPM 2026.
The change could ease stigma and fuel uptake, especially as oral weight loss drugs hit the market.
It targets pharma margins, PBM fees, and insurance subsidies to slash costs, which could redefine pricing power and consumer choice across the industry.
As funding concentrates among fewer companies, smaller players may need to sharpen differentiation.
Nurses top Gallup’s poll, but trust in clinicians strains under broader healthcare discontent.
As consumer health AI tools expand, companies must tread carefully or risk eroding consumer confidence.
In the crowded clinical market, trusted data, accuracy, and speed will shape adoption.
Weight and health improvements vanish within two years without sustained use, new research finds.
Walmart’s low-risk online health hub could funnel customers to retail and pharmacy without the heavy overhead of primary care.
Drugmakers could ease fears of transactional, unsupervised prescribing by collaborating with patients’ regular care teams.
Its new ChatGPT for Healthcare aims to win over physicians and health systems with HIPAA-safe, evidence-based tools.
Pharma branding agencies are using AI platforms to craft standout drug names while avoiding risk and streamlining time to market.
A new Rx refill program cuts out physicians, raising fears over safety—tougher regulatory oversight is likely to come.